Person: OCAK, TUĞBA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
OCAK
First Name
TUĞBA
Name
4 results
Search Results
Now showing 1 - 4 of 4
Publication Unintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib(BMJ Publishing Group, 2022-06-01) İnanç, N.; Abacar, K.; Öztürk, M. A.; Tufan, A.; Karadeniz, H.; Sarı, I.; Can, G.; Erez, Y.; Pehlivan, Yavuz; Dalkılıç, Ediz; Ocak, Tuğba; Cefle, A.; Yazıcı, A.; Şenel, A.; Akar, S.; Ediboğlu, E. Durak; Koca, S. S.; Sağır, R. Pişkin; Yılmaz, S.; Gülcemal, S.; Gündüz, O. Soysal; Başıbüyük, C. S.; Alkan, S.; Cesur, T. Y.; Önen, F.; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; OCAK, TUĞBA; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Romatoloji Bilim Dalı; FQP-0451-2022; JHC-5173-2023; FPQ-5941-2022Publication Focal segmental glomerulosclerosis: A single center experience(Galenos Yayıncılık, 2016-09-01) Ayar, Yavuz; Ersoy, Alparslan; Yıldız, Abdülmecit; Oruç, Ayşegül; Can, Fatma Ezgi; Ocakoğlu, Gökhan; Güllülü, Mustafa; Demirayak, Dilay; Bayrakçı, İsmail; Düger, Hakan; Ocak, Tuğba; Korkut, Bayram; Şahin, Ahmet Bilgehan; Akan, Mustafa; Eylemer, Eda; Ayar, Yavuz; ERSOY, ALPARSLAN; YILDIZ, ABDULMECİT; ORUÇ, AYŞEGÜL; Can, Fatma Ezgi; OCAKOĞLU, GÖKHAN; GÜLLÜLÜ, MUSTAFA; Demirayak, Dilay; Bayrakçı, İsmail; Düger, Hakan; OCAK, TUĞBA; Korkut, Bayram; ŞAHİN, AHMET BİLGEHAN; Akan, Mustafa; Eylemer, Eda; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0003-4607-9220; 0000-0002-0342-9692; 0000-0002-1114-6051; 0000-0001-5926-6813; 0000-0001-5478-3192; 0000-0002-7846-0870; 0000-0002-9252-8341; 0000-0002-0710-0923; 0000-0002-1953-7735; AGF-0767-2022; AAH-5054-2021; HIG-9032-2022; AAH-4002-2021; JSL-7718-2023; HLG-6346-2023; JGS-9425-2023; EQO-1344-2022; JLB-1564-2023; IZP-9361-2023; FPM-3131-2022; FFH-4157-2022; AAM-4927-2020; KUI-8062-2024; COF-1782-2022Aim: Focal segmental glomerulosclerosis (FSGS) is one of the most common glomerulonephritis (GNP) worldwide. Despite treatment, it may progress to end-stage renal disease. In the present study, we compared clinical and histopathological data on FSGS with primary and secondary GNP retrospectively.Methods: We retrospectively analyzed data on clinical and laboratory findings, treatment response, and risk factors associated with mortality in patients, who had been diagnosed with FSGS and other GNP via renal biopsy between January 2009 and December 2014. The average follow-up time was 22 (8-76) months.Results: FSGS and primary GNP were more frequently seen in males than in females (55.9% vs. 65.3%, p=0.033). Nephrotic syndrome was more common in patients with FSGS (41.2%) and primary GNP (57.7%), while chronic renal disease was more frequent in patients with secondary GNP (35%). In FSGS, the complete remission rate was 54.4%. 63.2% of patients had continued to receive treatment. According to the biopsy findings, interstitial inflammation and fibrosis were observed in 100% and 98.5% of patients with FSGS, respectively (p=0.010 and p<0.001, respectively). Serum albumin level was found to be increased and proteinuria, total cholesterol, triglyceride, and LDL levels to be decreased after treatment (p<0.001). Serum creatinine levels and type of GNP (secondary GNP) were detected to be 1.48 and 8.14 fold increased in mortality analysis, respectively.Conclusion: Renal biopsy is the gold standard for the diagnosis of glomerular diseases. Renal function at the time of diagnosis, follow-up and appropriate immunosuppressive therapy have effects on mortality and clinical progress in FSGS as is the case in all GNPs.Publication What predicts the recurrence in idiopathic granulomatous mastitis?(Springer London Ltd, 2023-06-10) Lermi, Nihal; Ekin, Ali; Ocak, Tuğba; Bozkurt, Zeynep Yılmaz; Ötegeçeli, Mehmet Akif; Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; LERMİ, NİHAL; EKİN, ALİ; OCAK, TUĞBA; Bozkurt, Zeynep Yılmaz; ÖTEGEÇELİ, MEHMET AKİF; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0003-3692-1293; 0000-0003-3692-1293; 0000-0002-7714-7786; GXH-1905-2022; JQW-5031-2023; AAG-7155-2021; FGB-0552-2022; FPM-3131-2022; IUR-9292-2023; IUS-1387-2023; IRX-3951-2023; JHC-5173-2023Introduction Idiopathic granulomatous mastitis (IGM) is a rarely seen chronic and benign disease of the breast. IGM usually emerges in women between 30 and 45 years of age and within the first 5 years after lactation. There is no consensus on the treatment of the disease. Steroids, immunosuppressive agents such as methotrexate and azathioprine, antibiotics, and surgical and conservative treatments can be preferred. In the present study, it was aimed to demonstrate the treatment options and follow-up data of the patients with IGM and to investigate the effective factors on recurrence if developed in the follow-up period.Materials and method The data of 120 patients diagnosed with idiopathic granulomatous mastitis were evaluated for this cross-sectional retrospective study. The demographic, clinical, treatment, and follow-up features of the patients were obtained from the file records.Results The median age value of the 120 female patients included in the study was 35 (24-67) years. Of the patients, 45%, 79.2%, 49.2%, and 15% had a past history of surgical intervention, steroid use, methotrexate use, and azathioprine use, respectively. Recurrent lesion developed after the treatment in 57 (47.5%) patients. The recurrence rate was 66.1% in the patients who underwent surgical intervention in the initial treatment. There was a statistically significant difference between the patients with and without recurrence regarding the presence of abscess, the presence of recurrent abscess, and having surgical intervention as the initial treatment in the past history. The rate of having surgery was statistically significantly higher compared with the administration of steroid therapy alone and the combination of steroid and immunosuppressive therapy in the initial treatment of the patients who developed recurrence. The rate of having surgery together with the administration of steroid and immunosuppressive therapy was statistically significantly higher than the administration of steroid and immunosuppressive therapies.Discussion Our study showed that surgical intervention and the presence of abscess increased recurrence in the treatment of IGM.Publication Unintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib(Lippincott Williams & Wilkins, 2023-12-01) Inanc, Nevsun; Abacar, Kerem Y.; Ozturk, Mehmet A.; Tufan, Abdurrahman; Karadeniz, Hazan; Sari, Ismail; Can, Gercek; Erez, Yesim; Cefle, Ayse; Yazici, Ayten; Senel, Abdurrahman S.; Akar, Servet; Durak-Ediboglu, Elif; Koca, Suleyman S.; Piskin-Sagir, Rabia; Yilmaz, Sema; Gulcemal, Semral; Soysal-Gunduz, Ozgul; Basibuyuk, Canberk S.; Alkan, Serdar; Cesur, Teoman Y.; Onen, Fatos; Dalkilic, Huseyin E.; DALKILIÇ, HÜSEYİN EDİZ; Pehlivan, Yavuz; PEHLİVAN, YAVUZ; Ocak, Tugba; OCAK, TUĞBA; 0000-0003-1096-7306; 0000-0003-4665-3421; 0000-0001-5815-6700; 0000-0003-2167-4509; 0000-0002-3734-1242; 0000-0003-4995-430X; 0000-0002-4839-3777; A-7613-2016; ITU-8307-2023; JFJ-3399-2023; AAT-3636-2020ObjectiveTo determine the rate of unintentional monotherapy (UM; switching to monotherapy from combination therapy of patients' own volition) in rheumatoid arthritis patients receiving tofacitinib and to evaluate tofacitinib survival rate.MethodsThis national, multicenter study included patients' data from the TURKBIO Registry. Demographics, clinical characteristics, disease duration and activity, comorbidities, and treatments were analyzed.ResultsData of 231 rheumatoid arthritis patients (84.8% female, median age, 56 years) were included; 153 were initially prescribed combination therapy and continued to their therapies; 31 were initially prescribed combination therapy but switched to monotherapy on their own volition (UM); 21 were initially prescribed monotherapy and switched to combination therapy; 26 were initially prescribed monotherapy and continued to their therapies. The rate of comorbidities at the time of data retrieval was higher in the UM group than in the combination group (83.3% vs. 60.3%, p = 0.031). Presence of comorbidities was a significant factor affecting switching to monotherapy (p = 0.039; odds ratio, 3.29; 95% confidence interval, 1.06-10.18). The combination and UM groups did not differ regarding remission rate assessed by Disease Activity Score 28-joint count C-reactive protein (60.5% and 70%, respectively; p = 0.328). Drug survival rates of the UM and combination groups did not differ. The median drug survival duration of tofacitinib was 27+ months with 1- and 4-year drug survival rates of 89.6% and 60.2%, respectively, in the UM group.ConclusionsAlthough 13.4% of the study population started monotherapy unintentionally, drug survival and remission rates of the UM and combination groups were not different. Comorbidity was a factor affecting transition from combination therapy to monotherapy.